Search Results (2)

Valerian possesses a multitude of pharmacological effects, including sedative and hypnotic properties, antihypertensive effects, antibacterial activity, and liver protection. Insomnia, one of the most prevalent disorders in contemporary society, significantly impacts people’s daily lives. This study aims to explore the anti-insomnia effects of valerian volatile oil (VVO) and investigate its potential mechanism of action through chemical analysis, network pharmacology, molecular docking, molecular dynamics simulations, and experimental validation. Through gas chromatography–mass spectrometry (GC-MS) analysis and drug-likeness screening, we identified 38 active compounds. Network pharmacology studies revealed that these 38 compounds might affect 103 targets associated with insomnia, such as monoamine oxidase B (MAOB), dopamine receptor D2 (DRD2), monoamine oxidase A (MAOA), interleukin 1β (IL1B), solute carrier family 6 member 4 (SLC6A4), prostaglandin-endoperoxide synthase 2 (PTGS2), and 5-hydroxytryptamine receptor 2A (HTR2A), which contribute to regulating the neuroactive ligand–receptor interaction, 5-hydroxytryptaminergic synapse, and calcium signaling pathways. The results of the molecular dynamics simulations indicated that bis[(6,6-dimethyl-3-bicyclo[3.1.1]hept-2-enyl)methyl] (E)-but-2-enedioate exhibited a stabilizing interaction with MAOB. The animal studies demonstrated that gavage administration of a high dose (100 mg/kg) of VVO significantly diminished autonomous activity, decreased sleep latency, and extended sleep duration in mice. Furthermore, the results of the Western blot experiment indicated that VVO interacts with MAOB, resulting in decreased expression levels of MAOB in the cerebral cortex. This study demonstrates the protective mechanism of VVO against insomnia through chemical analysis, network pharmacology, and experimental validation and extends the possible applications of VVO, which is a potential therapeutic ingredient for use in insomnia treatment. Full article

Biomass gasification to produce burnable gas now attracts an increasing interest for production flexibility in the renewable energy system. However, the biomass gasification technology using dual fluidized bed which is most suitable for burnable gas production still encounters problems of low production efficiency and high production cost. Here, we proposed a large-scale biomass gasification system to combine dual fluidized bed and high-temperature gas-cooled reactor (HTR) for co-production of hydrogen and synthetic natural gas (SNG). The design of high-temperature gas-cooled reactor biomass gasification (HTR-BiGas) consists of one steam supply module to heat inlet steam of the gasifier by HTR and ten biomass gasification modules to co-produce 2000 MW_th hydrogen and SNG by gasifying the unpretreated biomass. Software for calculating the mass and energy balances of biomass gasification was developed and validated by the experiment results on the Gothenburg biomass gasification plant. The preliminary economic evaluation showed that HTR-BiGas and the other two designs, electric auxiliary heating and increasing recirculated product gas, are economically comparative with present mainstream production techniques and the imported natural gas in China. HTR-BiGas is the best, with production costs of hydrogen and SNG around 1.6 $/kg and 0.43 $/Nm³, respectively. These designs mainly benefit from proper production efficiencies with low fuel-related costs. Compared with HTR-BiGas, electric auxiliary heating is hurt by the higher electric charge and the shortcoming of increasing recirculated product gas is its lower total production. Future works to improve the efficiency and economy of HTR-BiGas and to construct related facilities are introduced. Full article